Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 514 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft Versus Host Disease Oral Clear all
Completed No phase listed Observational

Preparatory Work to Assess Adherence to Oral Chemotherapy

NCT02895542
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
View directory record Official record
Conditions
Dialysis, Anemia
Interventions
Roxadustat, Oral Iron, IV Iron
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Northridge, California • Yuba City, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 15, 2026, 11:53 AM EDT
Not listed Phase 2 Interventional

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

NCT00036712
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions
management of therapy complications, pain therapy
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

NCT04504383
View directory record Official record
Conditions
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions
PN-943, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Tucson, Arizona • Garden Grove, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 15, 2026, 11:53 AM EDT
Completed No phase listed Observational

Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B

NCT01581554
View directory record Official record
Conditions
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 15, 2026, 11:53 AM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of Oral Cannabis in Chronic Spine Pain

NCT05052541
View directory record Official record
Conditions
Back Pain, Neck Pain
Interventions
THC/CBD, THC, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 84 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

NCT00366431
View directory record Official record
Conditions
Constipation
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Periodontitis With Er:YAG Laser

NCT03628872
View directory record Official record
Conditions
Generalized Moderate Chronic Periodontitis, Generalized Severe Chronic Periodontitis, Periodontal Diseases
Interventions
Scaling and root planing, Er:YAG Laser, Hand instruments
Procedure · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

NCT03815019
View directory record Official record
Conditions
Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
Interventions
Megestrol Acetate, iKanEat Behavioral Intervention
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
9 Months to 108 Months
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
8
States / cities
San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 15, 2026, 11:53 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, Acalabrutinib, Obinutuzumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Tucson, Arizona • Clovis, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 15, 2026, 11:53 AM EDT
Not listed Phase 2 Interventional

BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

NCT04482595
View directory record Official record
Conditions
COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19
Interventions
BIO 300 Oral Suspension, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

NCT02058277
View directory record Official record
Conditions
Healthy
Interventions
bosutinib or bosutinib + aprepitant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 15, 2026, 11:53 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting

NCT02303847
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lacey, Washington
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

NCT00946647
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
Panobinostat (LBH589), 5-Azacytidine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
8
States / cities
Augusta, Georgia • Indianapolis, Indiana • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 3 Interventional

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

NCT00071331
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
161
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Results available

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

NCT02468648
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Sofosbuvir, GS-5816
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 1 Interventional

NTX-301 in MDS/AML

NCT04167917
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Interventions
NTX-301
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

NCT04562155
View directory record Official record
Conditions
Refractory and/or Unexplained Chronic Cough
Interventions
BAY1817080, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Largo, Florida • White Marsh, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 15, 2026, 11:53 AM EDT
Recruiting Phase 3 Interventional

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07342478
View directory record Official record
Conditions
CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed, SLL (Small Lymphocytic Lymphoma), SLL, CLL, CLL Progression
Interventions
Rocbrutinib, Pirtobrutinib
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Skokie, Illinois • Bethesda, Maryland • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

NCT01581138
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
VX-222, telaprevir, ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

NCT01206478
View directory record Official record
Conditions
Chronic Oral Food Refusal
Interventions
Amitriptyline, Placebo, Megestrol
Drug
Lead sponsor
Ann Davis, PhD, MPH, ABPP
Other
Eligibility
9 Months to 8 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
3
States / cities
Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 15, 2026, 11:53 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception

NCT00349050
View directory record Official record
Conditions
Pain, Trigeminal Neuralgia, Neuropathic Pain
Interventions
laboratory pain assessment, transcranial magnetic stimulation
Device · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 15, 2026, 11:53 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

NCT02494479
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Prurisol, Placebo
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 15, 2026, 11:53 AM EDT